HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All (“HAFA”), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and ...

Core Insights - Harrow, a leading provider of ophthalmic disease management solutions in North America, is set to hold its Investor & Analyst Day on September 26, 2025, in New York, which will also be available via live webcast [1][2] Company Overview - Harrow offers a comprehensive portfolio of products addressing various ocular conditions, including dry eye disease, age-related macular degeneration, cataracts, glaucoma, and other retinal diseases [7] Event Details - The Investor & Analyst Day will feature presentations from Harrow's leadership team, covering the company's commercial portfolio, pipeline, and long-term vision, along with insights from key opinion leaders in the field [2][5] - The preliminary agenda includes topics such as Harrow's financial update, pipeline products, and expert perspectives on procedural sedation and specific ophthalmic conditions [5] Featured Speakers - Notable physician speakers include Dr. Paul Karpecki, Dr. Raj Patel, Dr. Seenu Hariprasad, and Dr. Maggie Jeffries, each bringing extensive experience in various areas of ophthalmology [3][4] Webcast Information - A live webcast of the event will be available, along with a replay and presentation materials posted on Harrow's investor relations page [6]

Group 1 - The article emphasizes the unique investment approach of "First Principles," which focuses on breaking down complex financial and technological problems to identify overlooked investment opportunities [1] - The analyst has a strong background in investment, private equity, and venture capital, demonstrating a proven track record of delivering strong returns [1] - The content on Seeking Alpha highlights emerging technologies, sustainable investing, and the intersection of innovation and finance, aiming to share insights and foster collaboration among investors [1]

Group 1 - The investing style described is termed "Fundamental Options," which combines fundamental analysis with options strategies [1] - The investment approach includes various strategies such as income-oriented investments, growth at a reasonable price, deep value, and dividend aristocrats [1] - The focus on long-term stock investments is complemented by 20-25 options strategies for purposes like hedging, bullish substitutes, neutral trades, trading volatility, and earnings-related trades [1] Group 2 - The analyst has a beneficial long position in HROW shares through stock ownership, options, or other derivatives [2] - The article expresses the author's own opinions and is not influenced by compensation from any company mentioned [2] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [3]

Core Viewpoint - Harrow, a leading provider of ophthalmic disease management solutions in North America, has announced a private offering of $250 million in senior unsecured notes due 2030, with an interest rate of 8.625% [1][2]. Group 1: Offering Details - The 2030 Notes will bear an interest rate of 8.625% per year, with interest payable semi-annually starting March 15, 2026, and maturing on September 15, 2030 [2]. - The offering price for the 2030 Notes is set at 100% of the principal amount [2]. - The offering is expected to close on September 12, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay a $107.5 million facility with Oaktree Fund Administration, redeem $75 million of outstanding 2026 Notes, and redeem $40.25 million of outstanding 2027 Notes [3]. - Remaining proceeds are anticipated to be allocated for general corporate purposes, including funding future strategic business development opportunities [3]. Group 3: Company Overview - Harrow, Inc. specializes in ophthalmic disease management solutions, offering a range of products for conditions such as dry eye disease, age-related macular degeneration, cataracts, and glaucoma [7]. - The company is committed to providing safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [7].

Core Viewpoint - Harrow has announced a private offering of $250 million in senior unsecured notes due 2030, alongside a new $40 million revolving credit facility, aimed at refinancing existing debt and supporting corporate purposes [1][2][3]. Group 1: Offering Details - The company is offering $250 million in senior unsecured notes due 2030, which will be guaranteed by its existing and future wholly-owned domestic restricted subsidiaries [1]. - The net proceeds from the offering will be used to repay a $107.5 million facility with Oaktree Fund Administration, redeem $75 million of 8.625% Senior Notes due 2026, and redeem $40.25 million of 11.875% Senior Notes due 2027 [3]. - The company has delivered a conditional notice to redeem all outstanding 2027 Notes on October 9, 2025, at a price of 102% of the principal amount plus accrued interest [4]. Group 2: Credit Facility - The company has entered into a commitment letter for a new revolving credit facility of up to $40 million, expected to close shortly after the issuance of the 2030 Notes [2]. - The new revolving credit facility is set to mature either 91 days prior to the earliest maturity date of the 2030 Notes or on the fifth anniversary of its closing [2]. Group 3: Redemption of Existing Notes - The company plans to redeem all outstanding 2026 Notes on a date between 30 to 60 days after delivering the redemption notice, at 100% of the principal amount plus a make-whole amount and accrued interest [5]. - Following the redemption, both the 2026 and 2027 Notes will be delisted from Nasdaq [4][5]. Group 4: Company Overview - Harrow is a leading provider of ophthalmic disease management solutions in North America, focusing on a comprehensive portfolio of products for various eye conditions [10].

Core Viewpoint - Harrow (HROW) shows potential as a strong investment opportunity due to significant upward revisions in earnings estimates, indicating an improving earnings outlook [1][2]. Earnings Estimate Revisions - The trend of increasing estimate revisions reflects growing analyst optimism regarding Harrow's earnings prospects, which is expected to positively influence its stock price [2]. - For the current quarter, Harrow is projected to earn $0.16 per share, marking a year-over-year increase of +233.3%. The Zacks Consensus Estimate has risen by 18.52% in the last 30 days, with two estimates increasing and no negative revisions [5]. - For the full year, the earnings estimate stands at $0.28 per share, representing a +171.8% change from the previous year. Similar to the current quarter, two estimates have been revised upward with no negative changes [6]. Zacks Rank - Harrow has achieved a Zacks Rank 1 (Strong Buy) due to favorable estimate revisions, which is a reliable indicator of potential stock performance. Historically, Zacks 1 Ranked stocks have delivered an average annual return of +25% since 2008 [3][7]. - Stocks with Zacks Rank 1 (Strong Buy) and Rank 2 (Buy) have been shown to significantly outperform the S&P 500 [7]. Stock Performance - Harrow's stock has increased by 10.7% over the past four weeks, driven by strong estimate revisions, suggesting that there may still be further upside potential [8].

Group 1 - Harrow (HROW) shares have increased by 10.7% in the past four weeks, closing at $40.01, with a mean price target of $61.31 indicating a potential upside of 53.2% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $8.32, where the lowest estimate is $52.20 (30.5% increase) and the highest is $76.00 (90% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 39% over the past month [11][12] Group 2 - HROW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] - While price targets can be misleading, the direction implied by them may serve as a useful guide for potential price movements [10][14]

Group 1 - The article discusses Stephen's background as a Registered Nurse (RN) and an MBA, emphasizing his analytical approach to healthcare and tech stocks through a proprietary system called the "Dizzy Framework" [1] - The "Dizzy Framework" is designed to mitigate common behavioral errors in investing, such as reacting to market noise or adhering too rigidly to prior beliefs, promoting a disciplined investment strategy [1] - Influences on Stephen's investment philosophy include concepts from "Superforecasting" and "Fooled by Randomness," which highlight the importance of quality and timing of information in investment decisions [1]

Core Insights - BAD BEAT Investing, led by Quad 7 Capital, has been providing investment opportunities for nearly 12 years, with a notable call in February 2020 to sell everything and go short, maintaining an average position of 95% long and 5% short since May 2020 [1] - The team consists of 7 analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences, focusing on both long and short trades [1] - The investment strategy emphasizes short- and medium-term investments, income generation, special situations, and momentum trades, aiming to educate investors on becoming proficient traders [1] Benefits of BAD BEAT Investing - Investors can learn to understand market dynamics, execute well-researched trade ideas weekly, and utilize 4 chat rooms for discussions [2] - Daily complimentary summaries of key analyst upgrades and downgrades are provided, along with education on basic options trading and access to extensive trading tools [2]